Brief: Synlogic Receives Orphan Drug Designation From FDA For Synb1934 For Treatment Of Phenylketonuria
09/05/2023 11:52
May 9 (Reuters) - Synlogic Inc SYBX.O :
* SYNLOGIC RECEIVES ORPHAN DRUG DESIGNATION FROM FDA FOR
SYNB1934
FOR TREATMENT OF PHENYLKETONURIA
Source text for Eikon: ID:nGNXX2dhT
Further company coverage: SYBX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Synlogic
See all newsBrief: Synlogic Receives Letter From Nasdaq Listing Qualifications Department On Nov 21 - SEC Filing
Brief: Synlogic Inc Files For Mixed Shelf Of Up To $150 Million – SEC Filing
Synlogic Inc reports results for the quarter ended September 30 - Earnings Summary
Synlogic Inc expected to post a loss of 10 cents a share - Earnings Preview
Synlogic Inc reports results for the quarter ended in January - Earnings Summary